Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Cells ; 8(1)2019 01 16.
Artigo em Inglês | MEDLINE | ID: mdl-30654525

RESUMO

Parkinson's disease, like other neurodegenerative diseases, exhibits two common features: Proteinopathy and oxidative stress, leading to protein aggregation and mitochondrial damage respectively. Because both protein aggregates and dysfunctional mitochondria are eliminated by autophagy, we suggest that inadequate clearance may couple the two phenomena. If a neuron's autophagy machinery is overwhelmed, whether by excessive oxidative stress or by excessive protein aggregation, protein aggregates and dysfunctional mitochondria will both accumulate. Parkinson's disease may provide a unique window into this because there is evidence that both sides contribute. Mutations amplifying the aggregation of α-synuclein are associated with Parkinson's disease. Likewise, mutations in Parkin and PINK1, proteins involved in mitophagy, suggest that impaired mitochondrial clearance is also a contributing factor. Many have suggested that dopamine oxidation products lead to oxidative stress accounting for the dopaminergic selectivity of the disease. We have presented evidence for the specific involvement of hypochlorite-oxidized cysteinyl-dopamine (HOCD), a redox-cycling benzothiazine derivative. While toxins like 6-hydroxydopamine and 1-methyl-4-phenyl pyridinium (MPP+) have been used to study mitochondrial involvement in Parkinson's disease, HOCD may provide a more physiologically relevant approach. Understanding the role of mitochondrial dysfunction and oxidative stress in Parkinson's disease and their relation to α-synuclein proteinopathy is important to gain a full picture of the cause, especially for the great majority of cases which are idiopathic.


Assuntos
Estresse Oxidativo , Proteínas/efeitos adversos , Autofagia , Dopamina/química , Dopamina/metabolismo , Humanos , Mitocôndrias/patologia , Mitofagia
2.
Free Radic Biol Med ; 101: 44-52, 2016 12.
Artigo em Inglês | MEDLINE | ID: mdl-27682361

RESUMO

The dopamine oxidation product cysteinyl-dopamine has attracted attention as a contributor to the death of dopaminergic neurons in Parkinson's disease. Treatment of cysteinyl-dopamine with hypochlorite yields an even more cytotoxic product. This product has potent redox-cycling activity and initiates production of superoxide in PC12 cells. Taurine, which scavenges hypochlorite, protects PC12 cells from cysteinyl-dopamine but not from the hypochlorite product, suggesting that the product, not cysteinyl-dopamine itself, is toxic. Furthermore, rotenone, which enhances expression of the hypochlorite-producing enzyme myeloperoxidase, increases the cytotoxicity of cysteinyl-dopamine but not of the hypochlorite product. This suggests that dopamine oxidation to cysteinyl-dopamine followed by hypochlorite-dependent conversion to a cytotoxic redox-cycling product leads to the generation of reactive oxygen species and oxidative stress and may contribute to the death of dopaminergic neurons.


Assuntos
Citotoxinas/antagonistas & inibidores , Dopamina/análogos & derivados , Dopamina/toxicidade , Ácido Hipocloroso/antagonistas & inibidores , Superóxidos/antagonistas & inibidores , Taurina/farmacologia , Animais , Sobrevivência Celular/efeitos dos fármacos , Citotoxinas/toxicidade , Dopamina/farmacologia , Humanos , Ácido Hipocloroso/toxicidade , Modelos Biológicos , Oxirredução , Estresse Oxidativo , Células PC12 , Doença de Parkinson/metabolismo , Doença de Parkinson/patologia , Peroxidase/metabolismo , Ratos , Superóxidos/metabolismo
SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa